FindTrial
Sign In

Expression of DLL4 in serum of patients with chronic renal failure and maintenance hemodialysis and its clinical significance

Expression of DLL4 in serum of patients with chronic renal failure and maintenance hemodialysis and its clinical significance

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400081466
Enrollment
Unknown
Registered
2024-03-01
Start date
2024-03-01
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure

Interventions

Experimental group (Maintenance hemodialysis):None
Control group:None

Sponsors

Feng Xian People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Experimental group: 1. Maintain hemodialysis for >3 months, 3 times a week, 4 hours each time; 2. Vital signs are stable; 3. Sign informed consent. Control group: 1. Normal renal function; 2. Sign informed consent.

Exclusion criteria

Exclusion criteria: Experimental group: 1. Hospitalized due to serious infection or cardiovascular and cerebrovascular complications in the past month; 2. Tumor; 3. Liver function damage; 4. Cardiac insufficiency grade III or above. Control group: 1. Severe heart, lung, and liver dysfunction; 2. Tumor; 3. Severe infection in the past month.

Design outcomes

Primary

MeasureTime frame
Delta-like ligand 4;—

Countries

China

Contacts

Public ContactHuanhuan Yin

Feng Xian People's Hospital

919691323@qq.com+86 152 0521 1252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026